Company Genovis AB Nasdaq Stockholm

Equities

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Diagnostic & Testing Substances

Inactive Instrument

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

05-15	Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	CI

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

SEK in Million	2022	Weight	2023	Weight	Delta
Enzyme 87.6 %	85	83.1 %	139	87.6 %	+62.88%
Antibodies 12.4 %	17	16.9 %	20	12.4 %	+13.45%

SEK in Million	2022	Weight	2023	Weight	Delta
Other Countries 99.5 %	102	99.4 %	157	99.5 %	+54.72%
Sweden 0.5 %	1	0.6 %	1	0.5 %	+25.91%

Managers	Title	Age	Since
Fredrik Olsson CEO	Chief Executive Officer	53	31/12/01
Magnus Långberg DFI	Director of Finance/CFO	53	31/12/21
Rolf Lood CTO	Chief Tech/Sci/R&D Officer	40	31/12/16
Susanne Ahlberg IRC	Investor Relations Contact	67	31/12/06
Rikke Rytter SAM	Sales & Marketing	57	31/12/20
Jonathan Sjögren PRN	Corporate Officer/Principal	39	31/12/13

Members of the board	Title	Age	Since
Torben Vedel Stahl Jörgensen CHM	Chairman	72	04/05/20
Charlotta Ljungqvist BRD	Director/Board Member	63	31/12/18
Mikael Lönn BRD	Director/Board Member	75	31/12/13
Magnus Gustafsson BRD	Director/Board Member	52	31/12/21
Steve Jordan BRD	Director/Board Member	71	31/12/20

Name	Equities	%	Valuation
Mikael Lönn 14.50 %	9,490,653	14.50 %	35 M kr
Ålandsbanken Abp (Private Banking) 5.595 %	3,662,488	5.595 %	13 M kr
Joh. Berenberg, Gossler & Co. KG (Investment Management) 5.361 %	3,509,915	5.361 %	13 M kr
Teknik Innovation Norden Fonder AB 5.073 %	3,321,296	5.073 %	12 M kr
Andra AP-fonden 3.407 %	2,230,304	3.407 %	8 M kr
Aktia Bank Plc (Investment Management) 2.872 %	1,880,000	2.872 %	7 M kr
Danske Bank A/S (Investment Management) 2.188 %	1,432,310	2.188 %	5 M kr
Lonvia Capital SASU 1.117 %	731,481	1.117 %	3 M kr
Nordea Investment Management AB (Finland) 0.6269 %	410,416	0.6269 %	1 M kr
OP Asset Management Ltd. 0.4032 %	263,981	0.4032 %	960 072 kr

Genovis AB

Karl Johans väg 104

244 46, Kävlinge

+46 46 10 12 30

http://www.genovis.com

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	-9.89%	11.22B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.38%	7.58B
LANTHEUS HOLDINGS, INC.	+27.58%	5.48B
DIASORIN S.P.A.	+2.23%	5.38B
AUTOBIO DIAGNOSTICS CO., LTD.	-17.38%	3.77B
ANDON HEALTH CO., LTD.	+8.12%	2.6B
10X GENOMICS, INC.	-64.90%	2.35B
VITROLIFE AB	-8.53%	2.25B
MYRIAD GENETICS, INC.	+26.75%	2.2B

Diagnostic & Testing Substances